Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot - ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Table of Contents

.. 0 Table of Contents
... 1 Introduction
... 2 Evidence Profiles
... 3 EvidenceVariable Profiles
... 4 Group Profiles
... 5 Citation Profiles
... 6 ArtifactAssessment Profiles
... 7 Composition Profiles
... 8 Other Profiles
... 9 Profiles
... 10 Extensions
... 11 Terminologies
... 12 Examples
... 13 Downloads
... 14 Artifacts Summary
.... 14.1 Adaptation
.... 14.2 BaselineMeasureEvidence
.... 14.3 BaselineMeasureReport
.... 14.4 BookCitation
.... 14.5 BookPartCitation
.... 14.6 CertaintyOfEvidence
.... 14.7 Classification
.... 14.8 CohortDefinition
.... 14.9 Comment
.... 14.10 ComparativeBaselineMeasureEvidence
.... 14.11 ComparativeEvidence
.... 14.12 ComparativeEvidenceReport
.... 14.13 ComparativeEvidenceReportSubject
.... 14.14 ComparativeParticipantFlow
.... 14.15 ComparatorDefinition
.... 14.16 ComparatorGroup
.... 14.17 ComparatorOnlyEvidence
.... 14.18 Comparison
.... 14.19 CompositeRating
.... 14.20 DatabaseCitation
.... 14.21 DatabaseEntryCitation
.... 14.22 DataDictionary
.... 14.23 DatasetCitation
.... 14.24 DateAsRating
.... 14.25 EndpointAnalysisPlan
.... 14.26 EvidenceList
.... 14.27 EvidenceMap
.... 14.28 EvidenceR6
.... 14.29 EvidenceReport
.... 14.30 EvidenceReportSubject
.... 14.31 EvidenceSynthesisEvidence
.... 14.32 ExposureDefinition
.... 14.33 ExposureGroup
.... 14.34 GroupAssignment
.... 14.35 GroupR6
.... 14.36 Guideline
.... 14.37 InterventionOnlyEvidence
.... 14.38 JournalArticleCitation
.... 14.39 M11Report
.... 14.40 MetaanalysisEligibilityCriteria
.... 14.41 MetaanalysisOutcomeDefinition
.... 14.42 MetaanalysisStudyGroup
.... 14.43 NetEffectContribution
.... 14.44 NetEffectContributionList
.... 14.45 NetEffectContributions
.... 14.46 NetEffectEstimate
.... 14.47 NonComparativeEvidence
.... 14.48 OutcomeDefinition
.... 14.49 OutcomeImportance
.... 14.50 OutcomeList
.... 14.51 ParticipantFlow
.... 14.52 ParticipantFlowMeasure
.... 14.53 ParticipantFlowReport
.... 14.54 PreprintCitation
.... 14.55 Rating
.... 14.56 Recommendation
.... 14.57 RecommendationAction
.... 14.58 RecommendationEligibilityCriteria
.... 14.59 RecommendationJustification
.... 14.60 RecommendationPlan
.... 14.61 RiskOfBias
.... 14.62 SearchResults
.... 14.63 SearchStrategy
.... 14.64 SingleStudyEvidence
.... 14.65 SoaPlanDefinition
.... 14.66 SoftwareCitation
.... 14.67 StudyEligibilityCriteria
.... 14.68 StudyGroup
.... 14.69 SummaryOfFindings
.... 14.70 SummaryOfNetEffect
.... 14.71 SystematicReviewEligibilityCriteria
.... 14.72 SystematicReviewExcludedStudies
.... 14.73 SystematicReviewIncludedStudies
.... 14.74 VariableDefinition
.... 14.75 WebPageCitation
.... 14.76 ArtifactApprovalDate
.... 14.77 ArtifactAssessmentCompared
.... 14.78 ArtifactAssessmentDateAsRating
.... 14.79 ArtifactEffectivePeriod
.... 14.80 ArtifactLastReviewDate
.... 14.81 CharacteristicDescription
.... 14.82 CharacteristicDeterminedByExpression
.... 14.83 CharacteristicDeterminedByReference
.... 14.84 CharacteristicDurationDuration
.... 14.85 CharacteristicDurationRange
.... 14.86 CharacteristicInstancesQuantity
.... 14.87 CharacteristicInstancesRange
.... 14.88 CharacteristicMethod
.... 14.89 CharacteristicOffset
.... 14.90 CharacteristicTiming
.... 14.91 CharacteristicValueExpression
.... 14.92 CharacteristicValueUri
.... 14.93 CombinationMethod
.... 14.94 CombinationThreshold
.... 14.95 EvidenceVariableCategoryValueReference
.... 14.96 EvidenceVariableDefinition
.... 14.97 StatisticModelApplied
.... 14.98 StatisticModelExpression
.... 14.99 StatisticModelIncludeIf
.... 14.100 StatisticModelIntended
.... 14.101 StatisticModelValueCodeableConcept
.... 14.102 StatisticModelValueQuantity
.... 14.103 StatisticModelValueRange
.... 14.104 VariableDefinitionComparatorCategory
.... 14.105 VariableDefinitionRoleSubtype
.... 14.106 VariableDefinitionVariableRoleCode
.... 14.107 Evidence Variable Role Subtype Value Set
.... 14.108 Recommendation Justification Classifier Codes Value Set
.... 14.109 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)
.... 14.110 14706014 Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist.
.... 14.111 179899
.... 14.112 18160893 Wonder woman. Like my childhood heroine, Mrs. Betty also had amazing powers.
.... 14.113 18508207 A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal.
.... 14.114 19029421 Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer.
.... 14.115 19091394 Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial.
.... 14.116 19967827 Wonder woman was Argentine and her real name was Evita.
.... 14.117 22056152 Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial.
.... 14.118 22502942 Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial.
.... 14.119 23306100 Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.
.... 14.120 23452809 Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer.
.... 14.121 23604530 A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer.
.... 14.122 24598155 Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer.
.... 14.123 25301760 Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).
.... 14.124 26002607 Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra.
.... 14.125 26028518 Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
.... 14.126 26092557 Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non-castration-resistant prostate cancer.
.... 14.127 26244877 Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
.... 14.128 27222544 Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations.
.... 14.129 27308831 Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis.
.... 14.130 29114761 Web Exclusives. Annals Story Slam - How Wonder Woman Became My Alter Ego.
.... 14.131 29114762 Web Exclusives. Annals Story Slam - Wonder Woman Is a Cartoon Character.
.... 14.132 29202628 "I Kinda Feel Like Wonder Woman": An Interpretative Phenomenological Analysis of Pole Fitness and Positive Body Image.
.... 14.133 29357271 Using Hawkeye from the Avengers to communicate on the eye.
.... 14.134 29694275 A regressive formula of perversity: Wertham and the women of comics.
.... 14.135 29694302 Introduction: "Suffering Sappho!": Lesbian content and queer female characters in comics.
.... 14.136 30467172 Finding my inner Wonder Woman.
.... 14.137 33395
.... 14.138 34871555 What Can Wonder Woman Teach Radiologists?
.... 14.139 35243488 Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis.
.... 14.140 36491989 Another Georgia Wonder Woman: She Does More Astounding Tricks Than Did Lula Hurst.
.... 14.141 6907780 Career guide: to change what needs changing...doesn't take Wonder Woman.
.... 14.142 ADAS-Cog(11) EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version
.... 14.143 Anticoagulation for COVID-19 Combined RCTs in NEJM
.... 14.144 Bariatric_Surgery_Eligibility_Group_ADA_Recommendation_8_16
.... 14.145 Bariatric_Surgery_Eligibility_Group_ADA_Recommendation_8_17
.... 14.146 Bariatric_Surgery_RYGB_VSG_LAGB_BPD
.... 14.147 Baseline Measure Report: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.148 BaselineMeasureEvidence: Age in 2018 Norwegian Cohort Medical Group
.... 14.149 BaselineMeasureEvidence: Age in 2018 Norwegian Cohort Surgical Group
.... 14.150 BaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Medical Group
.... 14.151 BaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Surgical Group
.... 14.152 BookCitation: Crossing the Quality Chasm: A New Health System for the 21st Century
.... 14.153 BookPartCitation: Chapter 3 of Crossing the Quality Chasm: A New Health System for the 21st Century
.... 14.154 BookPartCitation: Chapter 3 of Crossing the Quality Chasm: A New Health System for the 21st Century - without baseCitation
.... 14.155 Certainty of Evidence Rating of 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)
.... 14.156 CIBIC+ EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version
.... 14.157 Citation for FEvIR Evidence 55: 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY)
.... 14.158 Citation for FEvIR Evidence 7637: Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill COVID-19
.... 14.159 Classification: Study Design for Association of Bariatric Surgery with Complications and Comorbidities JAMA 2018 Norwegian Cohort
.... 14.160 CohortDefinition_At_least_2_risk_factors_for_stroke
.... 14.161 CohortDefinition_BMI_27_5_32_4_in_Asian_Americans_who_do_not_achieve_durable_weight_loss_and_improvement_in_comorbidities_without_surgery
.... 14.162 CohortDefinition_BMI_30_34_9_in_persons_who_do_not_achieve_durable_weight_loss_and_improvement_in_comorbidities_without_surgery
.... 14.163 CohortDefinition_BMI_32_5_37_4_in_Asian_Americans_who_do_not_achieve_durable_weight_loss_and_improvement_in_comorbidities_without_surgery
.... 14.164 CohortDefinition_BMI_35_39_9_in_persons_who_do_not_achieve_durable_weight_loss_and_improvement_in_comorbidities_without_surgery
.... 14.165 CohortDefinition_BMI_35_and_at_least_1_obesity_related_comorbidity
.... 14.166 CohortDefinition_BMI_37_5_kg_m2_in_Asian_Americans
.... 14.167 CohortDefinition_BMI_criteria_for_ADA_surgery_recommendation
.... 14.168 CohortDefinition_Cancer_of_any_kind_except_basal_cell_skin_cancer_or_cancer_in_situ_unless_documented_to_be_disease_free_for_five_years
.... 14.169 CohortDefinition_Cardiovascular_event
.... 14.170 CohortDefinition_Heart_failure_based_on_Phenotypes
.... 14.171 CohortDefinition_Lower_BMI_criteria_for_ADA_surgery_consideration
.... 14.172 CohortDefinition_Nonfatal_myocardial_infarction
.... 14.173 CohortDefinition_Nonfatal_stroke
.... 14.174 CohortDefinition_Oxygen_saturation_96_on_Boots_Finger_Pulse_Oximeter
.... 14.175 CohortDefinition_Oxygen_saturation_96_on_Boots_Finger_Pulse_Oximeter_with_Ranges
.... 14.176 CohortDefinition_Proxy_criteria_for_surgical_candidates
.... 14.177 CohortDefinition_Severe_obesity
.... 14.178 Comment on Guideline: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes by Joanne Dehnbostel 2023-11-28T15:19:01.266Z
.... 14.179 ComparativeBaselineMeasureEvidence: Age in 2018 Norwegian Cohort Surgical Group vs. Medical Group
.... 14.180 ComparativeBaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Surgical Group vs. Medical Group
.... 14.181 ComparativeEvidence: All-cause mortality effect of bariatric surgery in 2022 meta-analysis
.... 14.182 ComparativeEvidence: Bariatric Surgery effect for ADA triple outcome at 5 years (Diabetes Surgery Study)
.... 14.183 ComparativeEvidence: Bypass surgery effects on Additional GI surgical procedure in JAMA 2018 Norwegian cohort study
.... 14.184 ComparativeEvidence: Bypass surgery effects on Myocardial infarction or stroke in Swedish Obese Subjects (SOS) study
.... 14.185 ComparativeEvidence: Bypass surgery effects on New onset depression in JAMA 2018 Norwegian cohort study
.... 14.186 ComparativeEvidence: Bypass surgery effects on Remission of diabetes in JAMA 2018 Norwegian cohort study
.... 14.187 ComparativeEvidence: Bypass surgery effects on Treatment with opioids in JAMA 2018 Norwegian cohort study
.... 14.188 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Courcoulas 2014
.... 14.189 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Courcoulas 2015
.... 14.190 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Cummings 2016
.... 14.191 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ding 2015
.... 14.192 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Dixon 2008
.... 14.193 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Halperin 2014
.... 14.194 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ikramuddin 2013
.... 14.195 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ikramuddin 2015
.... 14.196 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Liang 2013
.... 14.197 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Mingrone 2012 (DIBASY) trial
.... 14.198 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Mingrone 2015 (DIBASY) trial
.... 14.199 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Parikh 2014
.... 14.200 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Schauer 2012 (STAMPEDE) trial
.... 14.201 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Schauer 2014 (STAMPEDE) trial
.... 14.202 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Wentworth 2014
.... 14.203 ComparativeEvidence: Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis
.... 14.204 ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.205 ComparativeEvidenceReportSubject_Association_of_Bariatric_Surgery_vs_Medical_Obesity_Treatment_With_Long_term_Medical_Complications_and_Obesity_Related_Comorbidities_2018_Norwegian_Cohort
.... 14.206 ComparativeParticipantFlow: Dropout due to stopping intervention Lofexidine vs. Placebo in opioid detoxification trial
.... 14.207 ComparatorDefinition_NOT_Bariatric_Surgery_RYGB_VSG_LAGB_BPD
.... 14.208 ComparatorDefinition_Usual_care_pharmacologic_thromboprophylaxis
.... 14.209 ComparatorGroup_JAMA_2018_Norwegian_cohort_study_Control_cohort
.... 14.210 ComparatorGroup_Obese_patients_18_years_old_without_bariatric_surgery
.... 14.211 ComparatorOnlyEvidence: Additional GI surgical procedure without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 14.212 ComparatorOnlyEvidence: All-cause mortality without bariatric surgery in 2022 meta-analysis
.... 14.213 ComparatorOnlyEvidence: Myocardial infarction or stroke without bariatric surgery (Control Group) in Swedish Obese Subjects (SOS) study
.... 14.214 ComparatorOnlyEvidence: New onset depression without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 14.215 ComparatorOnlyEvidence: Remission of diabetes without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 14.216 ComparatorOnlyEvidence: Treatment with opioids without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study
.... 14.217 Comparison: Original and Adapted Recommendation: ADA Obesity Management Recommendation 8.16
.... 14.218 Composite Rating of FOI 153881 for Project FOI 112280
.... 14.219 Computable_Publishing_LLC
.... 14.220 COVID_19PneumoniaHospitalizedAdult
.... 14.221 Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill patients with COVID-19
.... 14.222 DatabaseCitation: Citation for FEvIR Platform
.... 14.223 DatabaseEntryCitation: ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort)
.... 14.224 DataDictionary: Measuring the Rate of Scientific Knowledge Transfer
.... 14.225 DataDictionary: phs003190
.... 14.226 DatasetCitation: Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and is Associated with Worse Outcomes
.... 14.227 DateOfFirstPublication Classification of FOI 153881 by Rachel Couban
.... 14.228 Delany-Moretlwe 2022 clinical trial
.... 14.229 EBMImplementationGuideProfile Value Set
.... 14.230 EGFR_45_59
.... 14.231 Evidence Based Medicine on FHIR Implementation Guide Code System
.... 14.232 EvidenceList: Effect estimates for meta-analysis (Biegel 2020, Wang 2020, SOLIDARITY)
.... 14.233 EvidenceList: Study results included in Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis
.... 14.234 EvidenceMap: Bariatric Surgery Summary of Findings Example for GIN 2022
.... 14.235 EvidenceReportSectionCode Value Set
.... 14.236 EvidenceReportSubject_Clinical_Outcomes_for_Effects_of_Bariatric_Surgery
.... 14.237 EvidenceVariableRoleSubtype Value Set
.... 14.238 Example EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version
.... 14.239 ExposureDefinition_Therapeutic_dose_anticoagulation_with_heparin
.... 14.240 ExposureGroup_JAMA_2018_Norwegian_cohort_study_Surgery_cohort
.... 14.241 ExposureVariable: Age (as continuous variable)
.... 14.242 ExposureVariable: Body Mass Index (as continuous variable)
.... 14.243 ExposureVariable: pht013093.v1.p1 Age at diagnosis
.... 14.244 ExposureVariable: pht013093.v1.p1 RACE
.... 14.245 ExposureVariable: pht013093.v1.p1 SEX
.... 14.246 ExposureVariable: pht013093.v1.p1 SUBJECT_ID
.... 14.247 ExposureVariable: pht013094.v1.p1 ANALYTE_TYPE
.... 14.248 ExposureVariable: pht013094.v1.p1 BODY_SITE
.... 14.249 ExposureVariable: pht013094.v1.p1 IS_TUMOR
.... 14.250 ExposureVariable: pht013094.v1.p1 SAMPLE_ID
.... 14.251 ExposureVariable: pht013094.v1.p1 SAMPLE_USE
.... 14.252 ExposureVariable: pht013094.v1.p1 Source_Type
.... 14.253 GroupAssignment: Bariatric Surgery vs. no bariatric surgery
.... 14.254 GroupAssignment: ExposureDefinition: Bariatric Surgery (RYGB, VSG, LAGB, BPD) vs. ComparatorDefinition: NOT Bariatric Surgery (RYGB, VSG, LAGB, BPD)
.... 14.255 GroupAssignment: high dose xanomeline vs. low dose xanomeline vs. placebo
.... 14.256 GroupAssignment: Roux-en-Y gastric bypass or Biliopancreatic Diversion vs. medical treatment
.... 14.257 GroupAssignment: Roux-en-Y gastric bypass surgery vs. Lifestyle-intensive medical management intervention alone
.... 14.258 GroupAssignment: Roux-en-Y gastric bypass vs. medical treatment
.... 14.259 GroupAssignment: Therapeutic-dose anticoagulation with heparin vs. Usual-care pharmacologic thromboprophylaxis
.... 14.260 Guideline: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes
.... 14.261 InterventionOnlyEvidence: Additional GI surgical procedure with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 14.262 InterventionOnlyEvidence: New onset depression with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 14.263 InterventionOnlyEvidence: Remission of diabetes with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 14.264 InterventionOnlyEvidence: Treatment with opioids with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study
.... 14.265 Investigator
.... 14.266 Investigator-by-treatment interaction for ADAS-Cog(11) ANCOVA
.... 14.267 IV remdesivir 200 mg then 100 mg/day for 9 days
.... 14.268 Joanne Dehnbostel's Adaptation Report of Recommendation: ADA Obesity Management Recommendation 8.16
.... 14.269 JournalArticleCitation: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes
.... 14.270 JournalArticleCitation: Association of Bariatric Surgery with Complications and Comorbidities JAMA 2018 Norwegian Cohort
.... 14.271 Justification for Recommendation: ADA Obesity Management Recommendation 8.16
.... 14.272 Justification for Recommendation: ADA Obesity Management Recommendation 8.17
.... 14.273 M11 Report Template Instructions
.... 14.274 MetaanalysisEligibilityCriteria_Mean_difference_in_HbA1c_effect_of_bariatric_surgery_in_type_2_diabetes_and_elevated_BMI_in_2016_meta_analysis
.... 14.275 MetaanalysisOutcomeDefinition_Mean_difference_in_HbA1c_between_Surgery_and_Medical_Lifestyle_groups_at_end_of_follow_up
.... 14.276 MetaanalysisStudyGroup_Effect_Estimates_for_Mortality_at_14_days_from_COVID19_Remdesivir_vs_Placebo_RCTs
.... 14.277 Mortality at 14 days
.... 14.278 NetEffectContribution: Additional GI surgical procedure for Example for GIN 2022
.... 14.279 NetEffectContribution: All-cause mortality for Example for GIN 2022
.... 14.280 NetEffectContribution: New onset depression for Example for GIN 2022
.... 14.281 NetEffectContribution: Nonfatal myocardial infarction or stroke for Example for GIN 2022
.... 14.282 NetEffectContribution: Remission of diabetes for Example for GIN 2022
.... 14.283 NetEffectContribution: Treatment with opioids for Example for GIN 2022
.... 14.284 NetEffectContributionList: Bariatric Surgery Example for GIN 2022
.... 14.285 NetEffectContributions_Bariatric_Surgery_Example_for_GIN_2022
.... 14.286 NetEffectEstimate: Bariatric Surgery Example for GIN 2022
.... 14.287 Norwegian Cohort Study Comparing Bariatric Surgery vs Medical Obesity Treatment for Long-term Medical Complications and Obesity-Related Comorbidities
.... 14.288 Organ support-free days
.... 14.289 Outcome Importance Rating 100 of All-cause mortality
.... 14.290 Outcome Importance Rating 30 of Nonfatal myocardial infarction or stroke
.... 14.291 Outcome Importance Rating 5 of New onset depression
.... 14.292 Outcome Importance Rating 5 of Remission of diabetes
.... 14.293 Outcome Importance Rating 5 of Treatment with opioids
.... 14.294 Outcome Importance Rating 8 of Additional GI surgical procedure
.... 14.295 OutcomeDefinition_American_Diabetes_Association_composite_triple_end_point_for_metabolic_control
.... 14.296 OutcomeDefinition_Diabetes_in_remission
.... 14.297 OutcomeDefinition_HbA1c_at_12_months
.... 14.298 OutcomeDefinition_HbA1c_at_24_months
.... 14.299 OutcomeDefinition_HbA1c_at_36_months
.... 14.300 OutcomeDefinition_HbA1c_at_60_months
.... 14.301 OutcomeDefinition_HbA1c_at_6_months
.... 14.302 OutcomeDefinition_New_onset_depression
.... 14.303 OutcomeDefinition_Nonfatal_myocardial_infarction_or_stroke
.... 14.304 OutcomeList: Clinical Outcomes for Effects of Bariatric Surgery
.... 14.305 OutcomeVariable: American Diabetes Association composite triple end point for metabolic control at 5 years
.... 14.306 OutcomeVariable: HbA1c at 12 months
.... 14.307 OutcomeVariable: HbA1c at 24 months
.... 14.308 OutcomeVariable: HbA1c at 36 months
.... 14.309 OutcomeVariable: HbA1c at 6 months
.... 14.310 OutcomeVariable: HbA1c at 60 months
.... 14.311 OutcomeVariable: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups at end of follow-up
.... 14.312 OutcomeVariable: New onset depression
.... 14.313 OutcomeVariable: Nonfatal myocardial infarction or stroke
.... 14.314 OutcomeVariable: Remission of diabetes
.... 14.315 OutcomeVariable_Additional_GI_surgical_procedure
.... 14.316 OutcomeVariable_All_cause_mortality
.... 14.317 OutcomeVariable_Treatment_with_opioids
.... 14.318 ParticipantFlow: 2018 Norwegian Cohort Excluded from Analysis
.... 14.319 ParticipantFlow: 2018 Norwegian Cohort Included in Analysis
.... 14.320 ParticipantFlow: 2018 Norwegian Cohort Medical Group Included in Analysis
.... 14.321 ParticipantFlow: 2018 Norwegian Cohort Surgical Group Included in Analysis
.... 14.322 ParticipantFlowMeasure: Dropout due to stopping intervention
.... 14.323 ParticipantFlowMeasure: Exclusion from analysis
.... 14.324 ParticipantFlowMeasure: Inclusion in analysis
.... 14.325 Participants_in_Anticoagulation_for_COVID_19_Combined_ATTACC_ACTIV_4a_and_REMAP_CAP_RCT_hospitalized_not_critically_ill
.... 14.326 Patients_who_are_hospitalized_for_COVID_19_and_who_are_not_critically_ill
.... 14.327 Placebo
.... 14.328 PlanDefinition for Recommendation: ADA Obesity Management Recommendation 8.16
.... 14.329 PlanDefinition for Recommendation: ADA Obesity Management Recommendation 8.17
.... 14.330 PreprintCitation: Nigella Sativa for COVID-19 OSF Preprint
.... 14.331 Recommendation Justification Code System
.... 14.332 Recommendation: ADA Obesity Management Recommendation 8.16
.... 14.333 Recommendation: ADA Obesity Management Recommendation 8.16-adapted
.... 14.334 Recommendation: ADA Obesity Management Recommendation 8.17
.... 14.335 Remdesivir
.... 14.336 Remdesivir_IV_200_mg_once_then_100_mg_once_daily_for_9_days
.... 14.337 Risk of Bias Assessment of Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill patients with COVID-19
.... 14.338 Risk Of Bias Type Value Set
.... 14.339 Scientific Evidence Code System (SEVCO) -- EXAMPLE VERSION for EBMonFHIR Implementation Guide
.... 14.340 SearchResults: PubMed search for Wonder Woman
.... 14.341 SearchStrategy_PubMed_and_Embase_search_for_van_Veldhuisen_2022_systematic_review
.... 14.342 SearchStrategy_PubMed_search_for_Wonder_Woman
.... 14.343 Severely_Obese_Adults_2018_Norwegian_Cohort
.... 14.344 SoaPlanDefinition: Follow-up assessment 3 months after study start
.... 14.345 SoftwareCitation: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter
.... 14.346 StudyCitation: 2022 Systematic Review of bariatric surgery mortality effect 35243488
.... 14.347 StudyEligibilityCriteria_Eligibility_Criteria_for_Bariatric_Surgery_Randomized_Trial_Diabetes_Surgery_Study
.... 14.348 StudyEligibilityCriteria_Eligibility_Criteria_for_DIBASY_Trial
.... 14.349 StudyEligibilityCriteria_Obese_patients_18_years_old
.... 14.350 StudyGroup_Bariatric_Surgery_Trial_Enrollment_Group
.... 14.351 StudyGroup_DIBASY_Trial_Enrollment_Group
.... 14.352 SummaryOfFindings: Bariatric Surgery Summary of Findings Example for GIN 2022
.... 14.353 SummaryOfNetEffect: Bariatric Surgery Summary of Net Effect Contributions Example for GIN 2022
.... 14.354 SystematicReviewEligibilityCriteria_ADT_and_Docetaxel_vs_ADT_alone_for_metastatic_hormone_naive_prostate_cancer
.... 14.355 SystematicReviewExcludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer
.... 14.356 SystematicReviewIncludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer
.... 14.357 Therapeutic-dose anticoagulation with heparin
.... 14.358 Type_2_diabetes_and_elevated_BMI_in_2016_meta_analysis
.... 14.359 WebPageCitation: A HEvKA Update Summary